Pfizer begins a mid-stage trial of a vaccine against omicron subvariant


Jul 27 (Reuters) – Pfizer Inc and its German partner BioNTech SE said on Wednesday they have launched a mid-stage study of a modified COVID-19 vaccine that targets both the original subvariant and Omicron’s BA.2.

Pfizer said the vaccine is in an early proof-of-concept study to gather more data.(https://bit.ly/3veWPKn)

Together, the BA.4 and BA.5 subvariants are estimated to make up nearly 95% of coronavirus cases in the United States in the week ending July 23.

The US Food and Drug Administration last month asked vaccine makers to focus on BA.4 and BA.5, the two currently dominant omicron sub-variants, for a possible booster dose in the fall season. .

(Reporting by Leroy Leo in Bengaluru; Editing in Spanish by Ricardo Figueroa)




infobae Sp

Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.
Back to top button